MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00415-022-11389-0

Медицинская библиотека · Journal of neurology · 2022

Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.

Stascheit Frauke, Grittner Ulrike, Hoffmann Sarah, Mergenthaler Philipp, Schroeter Michael, Ruck Tobias, Pawlitzki Mark, Blaes Franz, Kaiser Julia, Schara Ulrike, Della-Marina Adela, Thieme Andrea, Hagenacker Tim, Jacobi Christian, Berger Benjamin, Urban Peter P, Knop Karl Christian, Schalke Berthold, Lee De-Hyung, Kalischewski Petra, Wiendl Heinz, Meisel Andreas

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Patients with myasthenia gravis (MG) are potentially prone for a severe COVID-19 course, but there are limited real-world data available on the risk associated with COVID-19 for patients with MG. Here, we investigate whether current immunosuppressive therapy (IST) influences the risk of SARS-CoV-2 infection and COVID-19 severity.

METHODS

Data from the German myasthenia gravis registry were analyzed from May 2020 until June 2021 and included patient demographics, MG disease duration, comorbidities, current IST use, COVID-19 characteristics, and outcomes. Propensity score matching was employed to match MG patients with IST to those without, and multivariable binary logistic regression models were used to determine associations between IST with (1) symptomatic SARS-CoV-2 infection and (2) severe COVID-19 course, as measured by hospitalization or death.

RESULTS

Of 1379 patients with MG, 95 (7%) patients (mean age 58 (standard deviation [SD] 18) presented with COVID-19, of which 76 (80%) received IST at time of infection. 32 patients (34%) were hospitalized due to COVID-19; a total of 11 patients (12%) died. IST was a risk factor for hospitalization or death in the group of COVID-19-affected MG patients (odds ratio [OR] 3.04, 95% confidence interval [CI] = 1.02-9.06, p = 0.046), but current IST was not associated with a higher risk for SARS-CoV-2 infection itself.

DISCUSSION: In this national MG cohort study, current IST use was a risk factor for a severe disease course of COVID-19 but not for SARS-CoV-2 infection itself. These data support the consequent implementation of effective strategies to prevent COVID-19 in this high-risk group.

TRIAL REGISTRATION INFORMATION: German clinical trial registry ( https://www.drks.de ), DRKS00024099, first patient enrolled: February 4th, 2019.

Для цитирования: Stascheit Frauke, Grittner Ulrike, Hoffmann Sarah, Mergenthaler Philipp, Schroeter Michael, Ruck Tobias, Pawlitzki Mark, Blaes Franz, Kaiser Julia, Schara Ulrike, Della-Marina Adela, Thieme Andrea, Hagenacker Tim, Jacobi Christian, Berger Benjamin, Urban Peter P, Knop Karl Christian, Schalke Berthold, Lee De-Hyung, Kalischewski Petra, Wiendl Heinz, Meisel Andreas. Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.. Journal of neurology. 2022. DOI: 10.1007/s00415-022-11389-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.